BAJAJ BROKING

Notification close image
No new Notification messages
card image
Vikram Solar IPO is Open!
Apply for the Vikram Solar IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Anthem Biosciences Ltd

Pharmaceuticals

Offer Period :

14th to 16th Jul 2025

Anthem Biosciences Ltd IPO Details

IPO Date 14th to 16th Jul 2025 Minimum Investment ₹14820 / 1 Lots
Listing Date 2025-07-21 Maximum Investment ₹192660 / 13 Lots
Face Value ₹2 per share Total Issue Size ₹3395 Crores
Price ₹570 to ₹570 per share Fresh Issue ₹0 Crores
Lot Size 1 Lots (26 Shares) Offer For Sale ₹ [-]
Listing At BSE, NSE Retail Discount ₹ 0
Employee Discount ₹50 per Share Shareholding Pre Issue 561610051 Shares
Issue Type Book Building Shareholding Post Issue 561610051 Shares
IPO Date 14th to 16th Jul 2025
Listing Date 2025-07-21
Face Value ₹2 per share
Price ₹570 to ₹570 per share
Lot Size 1 Lots (26 Shares)
Listing At BSE, NSE
Total Issue Size ₹3395 Crores
Employee Discount ₹50 per share
Issue Type Book Building
Minimum Investment ₹14820 / 1 Lots
Maximum Investment ₹192660 / 13 Lots
Fresh Issue ₹0 Crores
Offer For Sale ₹[-] Crores
Retail Discount ₹0 Crores
Shareholding Pre Issue 561610051 Shares
Shareholding Post Issue 561610051 Shares

About Anthem Biosciences Ltd IPO

Incorporated in 2006, Anthem Biosciences Limited operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities spanning drug discovery, development, and manufacturing. The company caters to a global customer base, including emerging biotech firms and large pharmaceutical companies. Its product portfolio includes fermentation-based active pharmaceutical ingredients (APIs) such as enzymes, probiotics, peptides, biosimilars, and vitamin analogues. As of September 30, 2024, Anthem was involved in 196 projects, including discovery, early and late-phase, and commercial manufacturing projects. The company supported ten commercial molecules from discovery through production.
 

Anthem Biosciences’ CRDMO platform comprises five primary modalities—RNAi, ADC, peptides, lipids, and oligonucleotides—along with four manufacturing capabilities: custom synthesis, flow chemistry, fermentation, and biotransformation. As of March and September 2024, the company served over 550 and 425 customers respectively, across more than 44 countries, including the U.S., Japan, and Europe. The company’s workforce includes 600 professionals from diverse scientific disciplines, and it holds one patent in India, seven internationally, with 24 global patent applications pending.

Founding Year: 2006

Managing Director: [-]

Anthem Biosciences Limited Timeline

Important dates for allocation and IPO listing.

14th Jul

IPO Opens

16th Jul

IPO Close

17th Jul

Allotment Date

18th Jul

Initiation of Refund

18th Jul

Credit of Shares to Demat Account

21st Jul

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 76.87 74.69
Public Group 23.13 25.31

Anthem Biosciences Ltd IPO Reservation

QIB Shares Offered 11883334(19.95%)
NII (HNI) Shares Offered 8912500(14.96%)
Retail Shares Offered 20795832(34.91%)
Anchor Investor Shares Offered 17825000(29.93%)
Total Shares Offered 59561404
Total Shares With Anchor Investor 59561404

Anthem Biosciences Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 26 ₹14820
Retail (Max) 13 338 ₹192660
S HNI (Min) 14 364 ₹207480
S HNI (Max) 67 1742 ₹992940
B HNI (MIN) 68 1768 ₹1007760

Anthem Biosciences Ltd IPO Anchor Investor Details

Bid Date 11 July 2025
Shares Offered 0
Anchor Portion Size 0

Anthem Biosciences Ltd IPO Registrar

KFin Techologies Ltd
Phone Number +91 40 6716 2222
Email Id einward.ris@kfintech.com
Our Website www.kfintech.com

Anthem Biosciences Ltd IPO Lead Manager

1. JM Financial Ltd

2. Citigroup Global Markets India Pvt Ltd

3. J.P.Mprgan India Pvt Ltd

4. Nomura Financial Advisors & Securities (India) P

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Anthem Biosciences Ltd Financial Information

Period Ended March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹2473.21 ₹1933.07 ₹1741.62
Reserves and Surplus ₹2361.4 ₹1821.26 ₹1627.52
Total Borrowing ₹108.95 ₹166.59 ₹113.93

Anthem Biosciences Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 12543518 2291095976 182.6518
Non Institutional Investors (NIIs) 9407639 398469578 42.356
NII(Bid amount of more than Ten Lakh Rupees) 6271760 306918534 48.9366
NII(Bid amount of more than 2 Lakh < 10 Rupees) 3135879 91551044 29.1947
Retail Individual Investors (RIIs) 21951158 123847828 5.642
Total 44070682 2814524128 63.8639

Strength of Anthem Biosciences Ltd

1. The Company offers comprehensive one-stop service capabilities across the drug life cycle (drug discovery, development and manufacturing) for both small molecules and biologics and it is the fastest growing Indian CRDMO.

2. Its innovation-focused approach has enabled it to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.

5. Wide specialty ingredients portfolio, well positioned to capitalize on the large market opportunity for niche specialty ingredients such as GLP-1, fermentation-based products,

6. Fully built-out automated manufacturing infrastructure with a consistent regulatory compliance track record.

Risks Involved

1. Its business depends on the demand for the company CRDMO services, which contributed to 81.65% of its revenue from operations in Fiscal 2025. Any adverse impact on its CRDMO customers' business or the industries in which they operate may have a material adverse effect on the company business.

2. Developmental and commercial manufacturing contributed to 70.78% of its revenue from operations and 71.90% of the company total number of Projects in Fiscal 2025. Its business may be adversely affected by a failures in early phase developmental Projects or a failures to develop or manufacture commercially viable drugs, including for reasons that are not within its control.

3. Its financial performance is dependent on the success of the molecules the company manufacture, and its revenue from operations decreased in Fiscal 2023 compared to Fiscal 2022, partly attributable to the failures of a phase III molecule and withdrawal of a commercialized molecule. Accordingly, any unfavorable developments affecting these molecules' success rates, including failures to obtain the required regulatory approvals or withdrawal of commercialized molecules, may have an adverse impact on its business, financial condition, results of operations and prospects.

4. The company is subject to rapid advancements in technology which requires continuous investments. Its may not be successful in developing new technologies and improving its existing technologies to maintain the company competitive position. Any such failures to develop technologies may have a material and adverse impact on its business, financial condition and results of operations.

5. The company is subject to extensive government regulations, and if its fail to obtain, maintain or renew our statutory and regulatory licenses, permits and approvals required to operate the company business, results of operations and cash flows may be adversely affected.

6. The company depends on certain key customers for a significant portion of its revenues (its top 5 and top 10 customers contributed to 70.92% and 77.33%, respectively, of its revenue from operations in Fiscal 2025). Any inability to retain the company key customers or decrease in revenues from any of its key customers could negatively affect the company business and results of operations.

7. The company is dependent on its arrangements with DavosPharma, the affiliate of one of its Shareholders and also a Selling Shareholder, for the company business and marketing activities in the United States.

8. The company faces the risk of losing manufacturing revenue from services supplied to innovator pharmaceutical companies after the expiry of their patent protection period, which may lead to the availability of alternative formulations at a lower cost.

9. The company is highly dependent on its skilled workforce, in particular its R&D team, for the company day-to-day operations. The loss of, or its inability to attract or retain such persons may lead to knowledge loss and have a material adverse effect on the company business performance.

10. The Offer Price of its Equity Shares, the company price-to-earnings ratio, its enterprise value to EBITDA ratio and the company market capitalisation to total revenue from operations ratio may not be indicative of the trading price of its Equity Shares upon listing on the Stock Exchanges subsequent to the Offer and, as a result, you may lose a significant part or all of your investment.

Why should you invest in

-

Anthem Biosciences Ltd Financials

Particulars For the financial year ending (in ₹ million)
  2025 2024 2023
Total Assets 2807.58 2398.11 2014.46
Total Liabilities 2807.58 2398.11 2014.46
Total Expenses 1273.42 1005.75 698.5
Total Revenue 
1930.29 1483.07 1133.99
Profit After Tax 451.26 367.31 385.18
EBITDA 756.57 568.68 567.76
Adjusted EBITDA 0 0 0

Anthem Biosciences Limited IPO Contact Details

Anthem Biosciences Ltd IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
2025-07-21 544449 ANTHEM
INE0CZ201020
₹570 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹570 ₹570
Open ₹723.1 ₹723.05
Low ₹723.05 ₹723.05
High ₹746.7 ₹747
Low ₹723.05 ₹723.05

Industry Outlook of Anthem Biosciences IPO

  • The global pharmaceutical industry is anticipated to reach a value of USD 2,076.0 billion by 2029, as per the F&S Report.

  • Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) are increasingly combining their offerings.

  • This shift is leading to the development of integrated Contract Research, Development and Manufacturing Organization (CRDMO) business models.

  • The Indian CRDMO industry is expected to expand at a compound annual growth rate (CAGR) of 13.4% between 2024 and 2029.

  • By 2029, the Indian CRDMO market is estimated to reach a value of USD 15.4 billion.

  • The projected growth rate for India exceeds the global industry CAGR of 9.1% and several other regions.

  • Despite this trend, pharmaceutical companies continue to face challenges.

  • Key concerns include pricing pressures, a limited success rate of experimental compounds reaching commercialisation, and rising regulatory requirements.


Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Anthem Biosciences IPO.

Frequently Asked Questions

What is Anthem Biosciences Ltd IPO?

Answer Field

Anthem Biosciences Ltd IPO is a Mainboard IPO of 5,95,61,404 equity shares of a face value of ₹2 aggregating up to ₹3395 Crores. The issue is priced at ₹570 to ₹570 per share. The minimum order quantity is 26 Shares. The IPO opens on July 14, 2025, and closes on July 16, 2025. KFin Techologies Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Anthem Biosciences Ltd IPO will open?

Answer Field

The Anthem Biosciences Ltd IPO opens on July 14, 2025 and closes on July 16, 2025.

What is the lot size of Anthem Biosciences Ltd?

Answer Field

Anthem Biosciences Ltd lot size is 26 shares, and the minimum amount required is ₹14,820.

How to apply for Anthem Biosciences Ltd IPO?

Answer Field

You can apply in Anthem Biosciences Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Anthem Biosciences Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Anthem Biosciences Ltd IPO will be done on July 17, 2025, and the allotted shares will be credited to your demat account by July 18, 2025.

When is Anthem Biosciences Ltd IPO listing date?

Answer Field

The Anthem Biosciences Ltd listing date is July 21, 2025.

Who is the registrar of Anthem Biosciences Ltd IPO?

Answer Field

The registrar of Anthem Biosciences Ltd IPO is KFin Techologies Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

JM Financial Ltd,Citigroup Global Markets India Pvt Ltd,J.P.Mprgan India Pvt Ltd,Nomura Financial Advisors & Securities (India) P will be the book-running lead manager of this IPO.

What is the fresh issue of Anthem Biosciences Ltd IPO?

Answer Field

The fresh issue size is ₹[-] Crores equity shares.

What minimum lot size can retail subscribers subscribe to Anthem Biosciences Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 26 shares and ₹14,820 amount.

How can I approve the UPI mandate request for Anthem Biosciences Ltd IPO?

Answer Field

To apply for Anthem Biosciences Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Anthem Biosciences Ltd?

Answer Field

The price of each Anthem Biosciences Ltd share will be ranging in between ₹570 to ₹570 per share.

What is the cut-off time for the UPI mandate for Anthem Biosciences Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, July 16, 2025.

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • STUDIO LSD LIMITEDSME IPO

  • Bidding Dates

    18th Aug 2025 - 8th Aug 2025

  • Price Range

    ₹51.0 - 54.0

  • IPO Size

    ₹70,13,00,000

  • Apply Now
  • VIKRAM SOLAR LIMITEDMainboard IPO

  • Bidding Dates

    19th Aug 2025 - 8th Aug 2025

  • Price Range

    ₹315.0 - 332.0

  • IPO Size

    ₹20,79,37,00,000

  • Apply Now
  • GEM AROMATICS LIMITEDMainboard IPO

  • Bidding Dates

    19th Aug 2025 - 8th Aug 2025

  • Price Range

    ₹309.0 - 325.0

  • IPO Size

    ₹4,51,25,00,000

  • Apply Now
  • PATEL RETAIL LIMITEDMainboard IPO

  • Bidding Dates

    19th Aug 2025 - 8th Aug 2025

  • Price Range

    ₹237.0 - 255.0

  • IPO Size

    ₹2,42,76,00,000

  • Apply Now
  • SHREEJI SHIPPING GLOBAL LIMITEDMainboard IPO

  • Bidding Dates

    19th Aug 2025 - 8th Aug 2025

  • Price Range

    ₹240.0 - 252.0

  • IPO Size

    ₹4,10,71,00,000

  • Apply Now
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • JSW CEMENT LIMITEDMainboard IPO

  • Bidding Dates

    7th Aug 2025 - 8th Aug 2025

  • Price Range

    ₹139.0 - 147.0

  • IPO Size

    ₹36,00,00,00,000

  • Invest Now
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)
  • Lorem Ipsum
  • JSW CEMENT LIMITEDMainboard IPO

  • Issue Price

    147.00

  • Listing Day Close

    146.05

  • Listing Day (Gain/Loss)

    -0.68

  • KNOWLEDGE REALTY TRUSTMainboard IPO

  • Issue Price

    100.00

  • Listing Day Close

    106.18

  • Listing Day (Gain/Loss)

    6.00

  • ESSEX MARINE LIMITEDSME IPO

  • Issue Price

    54.00

  • Listing Day Close

    41.04

  • Listing Day (Gain/Loss)

    -24.07

We have something for everyone

Explore more Investment options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text